Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $14.6852W HIGH $24.68
Volume
2.74 M
Value Traded
45.69 M
Short % Float
22.68%
-7.58%Week
-18.77%1 Month
-2.32%3 Month
-20.5%6 Month
-78.94%5 Year
-60.7%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.78 B
EPS (TTM)
-2.52
P/E Ratio
-
Ent. Value
1.84 B
Total Shares
105.60 M
Float Shares
100.44 M
Insiders
4.91%
Institutions
106.16%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
SRPT Catalyst Timeline
Dated clinical, regulatory and corporate events for Sarepta Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Sarepta Therapeutics, Inc.
817Total events
13Upcoming
239Tier-1 (high impact)
2011 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Preclinical PoCSRP-1003Preclinical
SRP-1003 preclinical data show up to ~80% nuclear and cytoplasmic DMPK knockdown and correction of MBNL-dependent mis-splicing in DM1 models
myotonic dystrophy type 1 (DM1)source ↗
●Poster PresentationSRP-1003Presentation
Poster P-066: Preclinical Evaluation of SRP-1003: An alpha-v-beta-6 Integrin-Targeting siRNA Platform for Targeted Knockdown of DMPK in DM1
myotonic dystrophy type 1 (DM1)source ↗
▲Poster Presentationdelandistrogene moxeparvovecPresentation
Poster 103LBP: Functional and safety outcomes in older ambulatory DMD patients treated with delandistrogene moxeparvovec
Duchenne muscular dystrophysource ↗
▲Biomarker Datadelandistrogene moxeparvovecClinical Data
ENDEAVOR Cohort 6: robust micro-dystrophin expression and sarcolemmal localization at 12 weeks in patients aged 2 to <3 years
Duchenne muscular dystrophysource ↗
●Long Term Datadelandistrogene moxeparvovecClinical Data
52 patients continue to be followed in EXPEDITION three years after ELEVIDYS treatment
Duchenne muscular dystrophysource ↗
●Safety Data Updatedelandistrogene moxeparvovecClinical Data
Safety profile of delandistrogene moxeparvovec remained consistent with no new signals identified
Duchenne muscular dystrophysource ↗
◆Poster Presentationdelandistrogene moxeparvovecPresentation
Pooled analysis of micro-dystrophin expression and muscle MRI with functional outcomes presented at NMSG 2026
Duchenne muscular dystrophysource ↗
◆Poster PresentationSRP-1003Presentation
Interim findings from Phase 1/2 study of SRP-1003 in DM1 presented at NMSG 2026
Myotonic Dystrophy Type 1source ↗
◆Poster PresentationSRP-1001Presentation
Interim findings from Phase 1/2 study of SRP-1001 in FSHD1 presented at NMSG 2026
FSHD1source ↗
◆Timing GuidancePresentation
Sarepta abstracts and presentations to be available on Sarepta.com following NMSG embargo
●R&D DayPresentation
Sarepta senior management fireside chat at Morgan Stanley 24th Annual Global Healthcare Conference
●Management ChangeCorporate
Michael Severino, MD appointed Chief Executive Officer and Board member
▲FDA Filing AcceptedRegulatory Filing
FDA acceptance of sNDA for AMONDYS 45
Duchenne muscular dystrophysource ↗
▲FDA Filing AcceptedRegulatory Filing
FDA acceptance of sNDA for VYONDYS 53
Duchenne muscular dystrophysource ↗
●Legal / SettlementCorporate
Recorded $39.0 million litigation contingency charge related to potential resolution of certain patent litigations
◆Oral PresentationPresentation
Sarepta Therapeutics presentation at RBC Capital Markets Global Healthcare Conference
▲IND ClearanceSRP-1005IND
Clinical trial application approved for SRP-1005
Huntington's diseasesource ↗
◆Trial InitiationSRP-1005Trial
First-in-human trial initiation expected in Q2 2026
Huntington's Diseasesource ↗
▲Topline ReadoutSRP-1001Clinical Data
First clinical data from Phase 1/2 study of SRP-1001 in FSHD1
facioscapulohumeral muscular dystrophy type 1 (FSHD1)source ↗
▲Topline ReadoutSRP-1003Clinical Data
First clinical data from Phase 1/2 study of SRP-1003 in DM1
myotonic dystrophy type 1 (DM1)source ↗
▲Full ResultsSRP-1001Clinical Data
First clinical data from Phase 1/2 ascending dose study of SRP-1001 for FSHD1
facioscapulohumeral muscular dystrophy type 1 (FSHD1)source ↗
▲Full ResultsSRP-1003Clinical Data
First clinical data from Phase 1/2 ascending dose study of SRP-1003 for DM1
myotonic dystrophy type 1 (DM1)source ↗
◆Enrollment UpdateELEVIDYSApprovedTrial
Screening and enrollment underway in ENDEAVOR Cohort 8 for non-ambulant individuals
Duchenne muscular dystrophysource ↗
◆Late-Breakerdelandistrogene moxeparvovecPresentation
Late-breaking oral presentation on delandistrogene moxeparvovec from EMBARK Part 1 up to 3 years post-infusion
Duchenne muscular dystrophysource ↗
◆Poster Presentationdelandistrogene moxeparvovecPresentation
Pooled safety analysis from Phase 1 to Phase 3 clinical trials with up to 7.5 years follow-up
Duchenne muscular dystrophysource ↗
◆Poster Presentationpatidistrogene bexoparvovecPresentation
Expression of SGCA and safety following treatment in LGMD2D/R3
LGMD2D/R3source ↗
◆Poster Presentationdelandistrogene moxeparvovecPresentation
Caregiver Global Impressions from EMBARK 2-year follow-up
Duchenne muscular dystrophysource ↗
◆Poster PresentationgolodirsenApprovedPresentation
Phase 3 topline results of golodirsen and casimersen vs placebo in ESSENCE
Duchenne muscular dystrophysource ↗
◆Poster PresentationcasimersenApprovedPresentation
Phase 3 topline results of golodirsen and casimersen vs placebo in ESSENCE
Duchenne muscular dystrophysource ↗
◆Poster PresentationEteplirsenApprovedPresentation
2025 interim analysis of EVOLVE: long-term safety and loss of ambulation
Duchenne muscular dystrophysource ↗
◆Oral PresentationPresentation
Sarepta senior management fireside chat at TD Cowen 46th Annual Health Care Conference
▲Product LaunchELEVIDYSApprovedPost-Market
Commercial launch of ELEVIDYS in Japan
Duchenne muscular dystrophysource ↗
▲Milestone PaymentELEVIDYSApprovedCorporate
$40 million milestone payment triggered by first commercial sale in Japan
Duchenne muscular dystrophysource ↗
▲Other Regulator MilestoneELEVIDYSApprovedEx-US Regulatory
Reimbursement listing on Japan's NHI price list
Duchenne muscular dystrophysource ↗
▲IND ClearanceSRP-1005IND
Medsafe approval of clinical trial application for SRP-1005
Huntington's Diseasesource ↗
▲IND ClearanceSRP-1005IND
Medsafe approves clinical trial application for SRP-1005
Huntington's Diseasesource ↗
●Oral PresentationELEVIDYSApprovedPresentation
Sarepta investor call to discuss EMBARK three-year results
Duchenne muscular dystrophysource ↗
▲Topline ReadoutELEVIDYSApprovedClinical Data
Positive topline three-year functional results from EMBARK Part 1-treated patients
Duchenne muscular dystrophysource ↗
◆Full ResultsELEVIDYSApprovedClinical Data
Analysis of three-year data ongoing, including crossover-treated patients two-year results
Duchenne muscular dystrophysource ↗
Past FDA Catalysts and PDUFA Decisions
How SRPT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | golodirsen; casimersen | Phase 3 data presentation | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
3
Drugs Scored
rNPV / MCap
Top Drug
Top 16%
Micro Cap(rank 106 of 656)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines from the latest annual filing)
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Pmo Products | |||
| Elevidys |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SRP-9003 Gene therapyNCT05876780 | Limb Girdle Muscular Dystrophy | Phase 3 | ACTIVE NOT_RECRUITING | 23 | Aug 28, 2028 | ||||||
| SRP-1005 Small moleculeNCT07536061 | Huntington's Disease | Phase 1 | RECRUITING | 32 | Nov 30, 2027 | ||||||
| Eteplirsen RNA therapyMarketedNCT03992430 | Duchenne Muscular Dystrophy | Phase 3 | ACTIVE NOT_RECRUITING | 341 | Oct 31, 2026 | ||||||
| delandistrogene moxeparvovec Gene therapyMarketedNCT06128564 | Duchenne Muscular Dystrophy | Phase 3 | ACTIVE NOT_RECRUITING | 815 | Feb 12, 2030 | ||||||
| SRP-5051 Small moleculeCompletedNCT03375255 | Muscular Dystrophy, Duchenne | Phase 1 | COMPLETED | 15 | Aug 19, 2019 | ||||||
| SRP-4045 Small moleculeMarketedNCT02530905 | Duchenne Muscular Dystrophy | Phase 3 | COMPLETED | 240 | Oct 3, 2018 | ||||||
| AVI-4658 Small moleculeMarketedNCT00844597 | Duchenne Muscular Dystrophy | Phase 2 | COMPLETED | 43 | Dec 1, 2010 | ||||||
| Amondys 45 Small moleculeMarketedNCT04179409 | Duchenne Muscular Dystrophy | Phase 2 | COMPLETED | 3 | Sep 1, 2023 | ||||||
| SRP-4053 Small moleculeMarketedNCT02310906 | Duchenne Muscular Dystrophy | Phase 1 | COMPLETED | 39 | Mar 25, 2019 | ||||||
| SRP-9004 Gene therapyCompletedNCT01976091 | Limb-Girdle Muscular Dystrophy, Type 2D | Phase 1 | COMPLETED | 6 | Mar 14, 2019 |
Clinical Trial Results
Readouts, endpoints and source filings for every SRPT program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ELEVIDYS (delandistrogene moxeparvovec) Accelerated | Duchenne muscular dystrophy | 2026-09-30 | durable benefits across multiple measures over two years compared to a well-matched external control groupRead More | Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with DuchenneRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Mayo StephenDirector | Sell | -7,239 1,765 held | $17.02 | 03/12/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SRPT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Casdin Capital, LLC | 0.4 % (-73.3 %) | 8.45 M | 470.00 K | -52.53% ( -520.10 K) |
SRPT Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SRPT ranks across every disease it competes in
Competitive Position is a premium feature
See how SRPT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSRPT News
SRPT▲ +1.8%today
Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting
Sarepta Therapeutics presented promising preclinical data for SRP-1003 at the Oligonucleotide Therapeutics Society Annual Meeting. The investigational siRNA demonstrated significant knockdown of pathogenic DMPK RNA in both the nucleus and cytoplasm, achieving up to 80% reduction. The results support the ongoing Phase 1/2 clinical study of SRP-1003 for myotonic dystrophy type 1 (DM1).
Read more →SRPTSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics has granted equity awards to 37 new employees as part of its 2024 Employment Commencement Incentive Plan. This initiative, approved by the Compensation Committee, aims to attract talent and enhance the company's workforce. The grants were made in compliance with Nasdaq Listing Rule 5635(c)(4).
Read more →SRPTSarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne
Sarepta Therapeutics presented new data at the World Muscle Society Congress, highlighting the safety and functional benefits of ELEVIDYS (delandistrogene moxeparvovec) in older ambulatory patients with Duchenne muscular dystrophy. The findings suggest significant improvements in patient outcomes, particularly in those aged 8 to 12, where functional decline is a concern.
Read more →SRPTSarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress
Sarepta Therapeutics will present new data on its Duchenne muscular dystrophy treatments at the 31st Annual Congress of the World Muscle Society in Hiroshima, Japan. The presentations include a late-breaking poster on the efficacy and safety of delandistrogene moxeparvovec in older, ambulatory patients. This event showcases Sarepta's commitment to advancing genetic medicine.
Read more →SRPTSarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27th Annual Neuromuscular Study Group Scientific Meeting
Sarepta Therapeutics will present new data from its neuromuscular portfolio at the 27th Annual Neuromuscular Study Group Scientific Meeting in San Antonio, Texas, from September 25-27, 2026. The presentation will include seven posters, featuring the first results from the Phase 4 ENDURE Study, which focuses on patients receiving delandistrogene moxeparvov.
Read more →SRPT▼ -6.9%on this news
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year
Sarepta Therapeutics has announced the recipients of Route 79, The Duchenne Scholarship Program, for the academic year 2026-2027. A total of 25 scholarships will be awarded, with 20 going to individuals living with Duchenne muscular dystrophy and five to their siblings. This initiative, now in its ninth year, aims to support education for those impacted by this rare disease.
Read more →SRPT▼ -6.9%on this news
Sarepta Therapeutics anuncia a los destinatarios de Route 79, el Programa de Becas de Duchenne, para el año académico 2026-2027
Sarepta Therapeutics has announced the recipients of the Route 79 Duchenne scholarship program for the 2026-2027 academic year. A total of 25 scholarships will be awarded, with 20 going to individuals diagnosed with Duchenne muscular dystrophy and five to their siblings. This program, now in its ninth year, aims to support those affected by the condition.
Read more →SRPTSarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
Sarepta Therapeutics announced its participation in the Morgan Stanley 24th Annual Global Healthcare Conference. Senior management will engage in a fireside chat on September 14 at 8:30 a.m. ET. The presentation will be available via live webcast and archived on the company's investor relations website.
Read more →SRPT▲ +5.3%on this news
Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments
Sarepta Therapeutics announced its financial results for the second quarter of 2026, highlighting a strong performance with revenues of $328.7 million. CEO Michael Severino expressed enthusiasm about the company's foundation and the positive impact of its therapies on patients. The report indicates promising opportunities for future growth.
Read more →SRPTSarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer
Sarepta Therapeutics has appointed Michael Severino, M.D., as its new CEO, effective July 28, 2026. Severino, who previously served as CEO of Tessera Therapeutics, will also join the company's Board of Directors. He succeeds Doug Ingram, who is retiring but will assist in the transition until the end of 2026.
Read more →SRPTSarepta Therapeutics to Announce Second Quarter 2026 Financial Results
Sarepta Therapeutics, Inc. will announce its second quarter 2026 financial results on August 5, 2026, after market close. Following the announcement, a conference call will be held at 4:30 p.m. E.T. to discuss the results. The event will be available via live webcast on the company's investor relations website.
Read more →SRPT▲ +5.6%on this news
Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®
Sarepta Therapeutics has announced that the FDA has accepted the supplemental New Drug Applications (sNDAs) for its products AMONDYS 45 and VYONDYS 53. This acceptance marks a crucial step towards potentially broadening treatment options for patients suffering from Duchenne muscular dystrophy. The company continues to focus on developing innovative therapies in this area.
Read more →SRPT▼ -7.7%on this news
Sarepta Therapeutics to Participate in Upcoming June 2026 Investor Conferences
Sarepta Therapeutics, Inc. has announced its participation in investor conferences scheduled for June 2026. Senior management will present at the Goldman Sachs conference, which will be available via live webcast on the company's investor relations website. The presentation will also be archived for 90 days for future viewing.
Read more →SRPTSarepta Therapeutics to Participate in Upcoming Investor Conferences
Sarepta Therapeutics is set to participate in upcoming investor conferences. Details regarding the specific events or topics of discussion were not provided in the article. This participation may provide insights into the company's future plans and developments.
Read more →SRPTSarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
Sarepta Therapeutics is scheduled to present at the RBC Capital Markets Global Healthcare Conference. The details regarding the presentation or any specific announcements were not provided in the article.
Read more →SRPT▲ +5.7%on this news
Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments
Sarepta Therapeutics has announced its financial results for the first quarter of 2026 along with recent corporate developments. The details of the financial performance and any significant updates regarding their operations or pipeline were not disclosed in the provided text. Further insights into the company's strategic direction may be expected in future communications.
Read more →SRPTSarepta Therapeutics to Announce First Quarter 2026 Financial Results
Sarepta Therapeutics, Inc. will announce its first quarter 2026 financial results on May 6, 2026, after market close. A conference call will follow at 4:30 p.m. E.T. to discuss these results. The event will be available via live webcast and archived for one year on the company's investor relations website.
Read more →SRPTWhen Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech
The biotechnology sector is transforming, with scientific advancements increasingly recognized as measurable financial assets. Fair-value accounting under U.S. GAAP allows companies to reflect clinical progress and commercialization timing in their financial statements. This shift is attracting institutional investors to clinical-stage biotech assets, emphasizing the importance of pipeline maturity in valuation.
Read more →About Sarepta Therapeutics, Inc.
Headquarters215 FIRST STREET, CAMBRIDGE, MA, 02142
BIOPHARMAWATCH ELITE PLUS
Trade the next SRPT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime